PIT-565is under clinical development by Novartis and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).
[Novartis](https://www.globaldata.com/company-profile/novartis-ag?scalar=true&utm_source=lgp5-loa&utm_medium=24-189865&utm_campaign=company-profile-hyperlink) conducts research in various disease areas through The [Novartis](https://www.globaldata.com/company-profile/novartis-ag?scalar=true&utm_source=lgp5-loa&utm_medium=24-189865&utm_campaign=company-profile-hyperlink) Institutes for BioMedical Research (NIBR). [Novartis](https://www.globaldata.com/company-profile/novartis-ag?scalar=true&utm_source=lgp5-loa&utm_medium=24-189865&utm_campaign=company-profile-hyperlink) is headquartered in Basel, Switzerland. [Buy the report here.](https://www.globaldata.com/store/report/pit-565-in-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-loa-and-ptsr-drug-analysis-483051?utm_source=lgp5-loa&utm_medium=24-189865&utm_campaign=LoA-report) [Novartis](https://www.globaldata.com/company-profile/novartis-ag?scalar=true&utm_source=lgp5-loa&utm_medium=24-189865&utm_campaign=company-profile-hyperlink) and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.